Hansoh's Olatorepatide Achieves 19.3% Weight Loss in Phase III Study
Hansoh Pharma's dual-agonist Olatorepatide demonstrated a 19.3% average weight loss at week 48 in a Chinese Phase III trial for weight management. The findings were presented at the European Association for the Study of Diabetes (EASD) annual meeting.
Hansoh Pharma announced Phase III clinical trial results for its novel weight management drug, Olatorepatide, at the European Association for the Study of Diabetes (EASD) annual meeting in Milan. The study focused on Chinese adults with overweight or obesity.
The LIGHTEN study, a randomized, double-blind, placebo-controlled trial involving 604 participants, showed that the 15 mg dose of Olatorepatide resulted in a mean weight loss of 19.3% after 48 weeks. Participants also experienced a mean waist circumference reduction of 16.0 cm. The study indicated that weight loss had not plateaued by week 48, suggesting potential for further benefits with extended treatment.
Olatorepatide is a dual-biased GLP-1/GIP receptor agonist designed to target appetite regulation and energy balance. The trial reported relatively low incidences of gastrointestinal side effects, with nausea at 7.8% and vomiting at 4.9% in the 15 mg group, which the company stated were lower than published data for similar agents. This profile supports its potential as a new therapy for obesity.
The drug candidate has advanced significantly in regulatory review. China's National Medical Products Administration (NMPA) has accepted Hansoh Pharma's New Drug Application for Olatorepatide for long-term weight management. Hansoh Pharma has also entered a collaboration with Regeneron for the global development and commercialization of the asset.